Tessera Defense and Homeland Security (HLSQ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Oct, 2026Executive summary
Oct. 8 supplement updates the proxy for the Oct. 20, 2026 special meeting with CEO and CFO awards conditioned on approval of Proposal 1.
Voting matters and shareholder proposals
The Board continues to recommend voting FOR Proposals 1 and 2; stockholders who already submitted a proxy need act only if they wish to change their vote.
Proposal 1 approval is a condition to the awards, alongside NYSE American listing approval, plan share availability and other specified approvals.
Board of directors and corporate governance
The Board and Compensation Committee approved personal employment agreements with CEO Michael Oster and CFO David Rokach on Oct. 7, after the proxy was filed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Tessera Defense and Homeland Security
- Plan expansion vote would unlock CEO equity awards tied partly to EBITDA/share targets.HLSQ
Proxy filing - Vote centers on a 5.315 million-share plan increase and potential dilution.HLSQProxy filing
- Vote sought to expand equity plan by 5.3M shares to support growth and retention.HLSQProxy filing
- First defense-tech revenue reported post-acquisitions, but liquidity and going concern risks persist.HLSQQ2 2026
- Proxy seeks approval for DFSL acquisition securities, reverse split, and auditor ratification.HLSQProxy filing
- Stockholders to vote on acquisition-related securities issuance, reverse split, and auditor change.HLSQProxy filing
- Shifted to defense/security tech, offering resale shares from acquisitions, with high dilution and financial risk.HLSQRegistration filing
- Merger, $50M financing, and clinical progress drive 2025 milestones amid ongoing losses and delisting risk.HLSQQ2 2024
- BX211 and BX004 show strong efficacy; $12M financing supports key clinical milestones.HLSQQ4 2024 & Study Result